Major advances in biologics production, cell and gene therapy, and regenerative medicine have prompted the need for highly accurate cell characterization. Also, the varying complexities of biological sources involved in these revolutionary studies and treatments require different optimized conditions, formulations, and bioprocessing steps depending on the intended use. To help address these challenges, the cell …

We’ve all heard the anecdotes about lab managers and their customers who demand results must be 1.) accurate, 2.) fast, and 3.) in-budget. Unfortunately, we also all know the stipulation that follows: “You can only pick two.” Fast and accurate, but not in-budget. Or, fast and in-budget, but not accurate… and so on. The pandemic …

Over the last three decades we’ve seen significant advances in the development and commercialization of therapeutic antibodies across numerous indications, including many cancers, as well as infectious, autoimmune, and metabolic diseases. During this time, the industry has grown exponentially and is now valued at billions of dollars. The first monoclonal antibody was approved by the …

Antibody therapeutics have grown in complexity over their 30-year history in clinical application. Newer generation antibody therapies target multiple modalities and are multi-specific in nature. A multi-specific protein therapeutic can function as an alternative to a cell therapy. For example, an antibody can be engineered to target a T cell receptor and a tumor receptor …

Drug development technology is evolving rapidly, creating new opportunities for the pharmaceutical industry to produce high-quality targeted large molecule drugs such as biologics and biosimilars. The combination of strict quality guidelines and a complex final product can lead to too much rejected product and slow the pace of drug development. Biologics tend to be large, …

To implement social distancing for COVID-19, many organizations and companies require fewer staff members to be in the laboratory simultaneously. Researchers may evaluate alternatives to widely used but tedious assay workflows. One example would be conventional techniques such as ELISA (enzyme-linked immunosorbent assay), which is used to detect and screen biomarkers, protein targets, and their …